1. Home
  2. UPBD vs NVAX Comparison

UPBD vs NVAX Comparison

Compare UPBD & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UPBD
  • NVAX
  • Stock Information
  • Founded
  • UPBD 1986
  • NVAX 1987
  • Country
  • UPBD United States
  • NVAX United States
  • Employees
  • UPBD N/A
  • NVAX N/A
  • Industry
  • UPBD Diversified Commercial Services
  • NVAX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • UPBD Consumer Discretionary
  • NVAX Health Care
  • Exchange
  • UPBD Nasdaq
  • NVAX Nasdaq
  • Market Cap
  • UPBD 1.6B
  • NVAX 1.3B
  • IPO Year
  • UPBD 1995
  • NVAX 1995
  • Fundamental
  • Price
  • UPBD $20.81
  • NVAX $8.62
  • Analyst Decision
  • UPBD Strong Buy
  • NVAX Buy
  • Analyst Count
  • UPBD 4
  • NVAX 7
  • Target Price
  • UPBD $37.25
  • NVAX $14.29
  • AVG Volume (30 Days)
  • UPBD 842.6K
  • NVAX 4.5M
  • Earning Date
  • UPBD 10-30-2025
  • NVAX 11-11-2025
  • Dividend Yield
  • UPBD 7.64%
  • NVAX N/A
  • EPS Growth
  • UPBD 78.87
  • NVAX N/A
  • EPS
  • UPBD 1.79
  • NVAX 2.54
  • Revenue
  • UPBD $4,481,986,000.00
  • NVAX $1,078,718,000.00
  • Revenue This Year
  • UPBD $10.15
  • NVAX $60.81
  • Revenue Next Year
  • UPBD $8.62
  • NVAX N/A
  • P/E Ratio
  • UPBD $11.41
  • NVAX $3.27
  • Revenue Growth
  • UPBD 7.49
  • NVAX 9.22
  • 52 Week Low
  • UPBD $19.65
  • NVAX $5.01
  • 52 Week High
  • UPBD $36.00
  • NVAX $13.34
  • Technical
  • Relative Strength Index (RSI)
  • UPBD 33.30
  • NVAX 50.15
  • Support Level
  • UPBD $20.53
  • NVAX $8.24
  • Resistance Level
  • UPBD $21.67
  • NVAX $9.60
  • Average True Range (ATR)
  • UPBD 0.87
  • NVAX 0.46
  • MACD
  • UPBD -0.59
  • NVAX -0.08
  • Stochastic Oscillator
  • UPBD 3.74
  • NVAX 28.62

About UPBD Upbound Group Inc.

Upbound Group Inc is an omnichannel platform company committed to elevating financial opportunity for all through inclusive, and technology-driven financial solutions that address the evolving needs and aspirations of consumers. It has three operating segments; The Rent-A-Center Business segment operates lease-to-own stores, the Acima segment offers the lease-to-own transaction to consumers who do not qualify for financing from the traditional retailer, and also offers the lease-to-own transaction through virtual offering solutions across e-commerce, digital, and mobile channels, Mexico segment offers lease-to-own stores in Mexico. The franchising segment offers the sale of rental merchandise to its franchisees. The company derives a majority of its revenue from the Acima segment.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: